VS-01 is under clinical development by Genfit and currently in Phase II for Ascites. According to GlobalData, Phase II drugs for Ascites have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VS-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VS-01 overview

VS-01 is under development for the treatment of acute-on-chronic liver failure (ACLF) (hepatic encephalopathy), ascites, organic acidemia disorder (OAD) and urea cycle disorders such as hyperammonemia. The drug candidate is a sterile, white liposomal suspension containing citric acid developed as peritoneal dialysis fluid. It is administered through the intraperitoneal route. It was also under development for decompensated liver cirrhosis.

Genfit overview

Genfit is a biopharmaceutical company that develops therapeutic and diagnostic solutions for metabolic and inflammatory diseases in liver and gastroenterology diseases. The company’s pipeline products include GFT505, NASH, TGFTX1 and Nitazoxanide (NTZ). Its TGFTX1 is a research program for neutrophilic asthma, chronic obstructive pulmonary disease and the asthma-COPD overlap syndrome (ACOS); NASH for treatment of liver diseases and NTZ for fibrotic diseases. Genfit develops diagnostic solutions in various therapeutic areas includes metabolic diseases, cholestatic liver diseases, inflammation and autoimmune diseases, and fibrotic diseases. The company’s research and development activities include multiple drug candidate research programs targeting novel mechanisms of action includes the inhibition of nuclear receptors ROR (a, ß, ?). It has presence in France and the US. Genfit is headquartered in Loos, France.

For a complete picture of VS-01’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.